Former pharmaceutical CEO Martin Shkreli has reportedly been subpoenaed to appear before the House Committee on Oversight and Government Reform next Tuesday.
A spokesperson for the committee did not immediately return a request for comment, but Bloomberg News reported that Shkreli has been subpoenaed to appear before the committee’s scheduled hearing on developments in the prescription drug market.
Rep. Elijah Cummings (D-Md.), the ranking member on the House Oversight Committee, has been at the forefront of congressional interest in rising drug prices and was one of the members who launched the Affordable Drug Pricing Task Force last year.
Cummings and Chairman Rep. Jason Chaffetz (R-Utah) sent Shkreli a letter earlier this month requesting documents and information related to Daraprim, a drug that was acquired by Shkreli’s former company Turing Pharmaceutical. The price subsequently rose drastically overnight. The committee asked that the documents be submitted by Jan. 22.
Shkreli has been a target of criticism from lawmakers as more congressional committees have looked into the rising costs of prescription drugs. At a December meeting of the Senate Special Aging Committee, ranking Democrat Claire McCaskill of Missouri referred to the former CEO as “Mr. Wu Tang,” in reference to his $2 million purchase of the only copy of the Wu-Tang Clan album in an auction.
Shkreli was arrested on securities fraud charges unrelated to Turing Pharmaceuticals in December.